Melanotan 2 Peptide Guide: The Tanning Peptide With Unexpected Side Effects

Melanotan II was developed in the early 1990s at the University of Arizona by researchers led by Victor Hruby and Mac Hadley. The original goal was skin cancer prevention. The logic was straightforward: if you could stimulate the body to produce more melanin (the pigment that darkens skin and protects against UV damage), you could reduce skin cancer rates in fair-skinned populations. The researchers started with alpha-melanocyte-stimulating hormone (alpha-MSH), a natural peptide that triggers melanin production. They created synthetic analogs that were more potent and longer-lasting. Melanotan I (now called afamelanotide, brand name Scenesse) eventually gained approval in Europe for erythropoietic protoporphyria, a rare photosensitivity disorder. Melanotan II took a different path. During clinical trials, researchers noticed something unexpected: male subjects were getting spontaneous erections. This was not a planned outcome. The erections were happening 1 to 5 hours after injection, often accompanied by yawning and stretching. This side effect was so pronounced that it redirected part of the research program toward sexual dysfunction, eventually producing bremelanotide. Meanwhile, MT-2 developed a massive underground market for tanning. It is sold online by research peptide suppliers, tanning clinics, and black-market vendors. Health authorities in the US, UK, Australia, and other countries have issued warnings against its use. The r/Melanotan2 subreddit has thousands of posts from users documenting their experiences, dosing protocols, and side effects.

MT-2 is a non-selective melanocortin receptor agonist. It binds to multiple melanocortin receptor subtypes (MC1R through MC5R), which is part of why it has such a wide range of effects. The tanning mechanism works through MC1R receptors on melanocytes, the cells that produce pigment in the skin. When MT-2 activates these receptors, the melanocytes ramp up eumelanin production. Eumelanin is the brown-black pigment that gives skin its tan. The result is darker skin that provides some natural UV protection. The sexual effects come from MT-2's activity at MC3R and MC4R receptors in the central nervous system. These receptors are involved in sexual arousal pathways in the brain. This is not a peripheral effect (it is not increasing blood flow to the genitals directly). It is a central nervous system effect that increases sexual desire and facilitates erections through neural pathways. MT-2 is typically injected subcutaneously every other day. Tanning effects can begin within 5 doses, though most protocols involve a loading phase of daily or every-other-day injections for 1 to 2 weeks, followed by maintenance doses 1 to 2 times per week. UV exposure (sunlight or tanning beds) dramatically accelerates and deepens the tan. Without some UV exposure, the tanning effect is muted.

The clinical data on MT-2 is limited but telling. A study published in the International Journal of Impotence Research found that MT-2 at a dose of 0.025 mg/kg produced erections in men with organic erectile dysfunction. The researchers described it as a “potent stimulator of male erections.“ This research directly led to the development of bremelanotide (Vyleesi), an FDA-approved treatment for hypoactive sexual desire disorder in premenopausal women. For tanning, the evidence is mostly anecdotal and community-based. Users consistently report measurable skin darkening within 1 to 2 weeks of starting MT-2, even with minimal sun exposure. With regular UV exposure during the loading phase, the tan deepens significantly and can persist for months after discontinuation because melanin is a stable pigment. Typical community dosing protocols:

• Loading phase: 0.5 mg subcutaneous injection, 2 to 3 times per week for 1 to 2 weeks
• Maintenance phase: 0.5 mg once per week or less
• Some users start lower (0.25 mg) to assess nausea tolerance
• UV exposure during loading accelerates results dramatically

The tanning effect is real and reproducible. The sexual side effect is also real and dose-dependent. Higher doses increase both the tanning response and the incidence of spontaneous erections and other side effects.

A user on r/Melanotan2 described the early experience as “day 1 through 3, you get transient nausea that lasts about 10 minutes, then face flushing for an hour or two. If you dose too aggressively, the nausea is brutal. Start low. By the end of week one, I could see my skin tone shifting. By week two with some sun, I had a tan that normally takes me a month to build.“ A user on r/tanning reported that “the side effects are real but manageable if you go slow. The nausea hits about an hour after injection and fades within 15 minutes. The spontaneous erections thing is not exaggerated. It caught me off guard the first time. The tan itself is impressive though. I am a natural redhead who has never tanned in my life, and MT-2 gave me a genuine bronze color. Just know what you are getting into.“ Individual responses vary. Some users tolerate MT-2 well with minimal side effects. Others find the nausea and flushing intolerable even at low doses.

• Visible skin darkening within 1 to 2 weeks, even with minimal UV exposure
• Deeper, more even tan that persists for months after stopping
• Reduced tendency to sunburn due to increased melanin protection
• Increased libido and sexual arousal (for some users, this is the primary draw)
• Potential to tan for the first time if you have very fair skin that normally only burns
• Lower effective dose over time as melanin accumulates in the skin

Melanotan I (afamelanotide) is the more selective cousin. It primarily targets MC1R and produces tanning without the sexual side effects or as much nausea. Some researchers use MT-2 for the loading phase and switch to Melanotan I for maintenance to reduce ongoing side effects. Afamelanotide is actually approved in Europe, which gives it a cleaner regulatory profile. BPC-157 is sometimes included in protocols to manage the gastrointestinal side effects of MT-2. BPC-157 supports gut lining integrity and has anti-nausea properties in some research models. The pairing is practical rather than mechanistic. PT-141 (bremelanotide) is the active metabolite derived from MT-2's sexual effects. If someone is using MT-2 primarily for sexual function rather than tanning, PT-141 is the more targeted option. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder in women. It works on the same MC3R/MC4R pathways without the melanocyte activation. GHK-Cu is sometimes added to tanning and skin health protocols. It supports collagen production and skin repair, which complements the cosmetic goals of MT-2 users who are focused on appearance.